Allergy immunotherapies market: Driving factors, industry challenges, segmentation, key vendor analysis, leading countries, and market size and forecast 2023-2027 - Technavio

NEW YORK, Jan. 23, 2023 /PRNewswire/ --
In-depth analysis provided in the report includes:

• Current and future market trends to highlight market conditions
• Comparative analysis of the market and its segments for the historic period of 2017 - 2021
• Market drivers and market impediments and their impact on market growth
• Positioning of market players and their business strategy analysis
• Download a sample now!

 Global allergy immunotherapies market size & segmentation analysis

The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecasted to increase by USD 1,010.37 million. The allergy immunotherapies market is segmented based on product, type, and geography.

• Based on product, the allergy immunotherapies market is segmented into SCIT and SLIT
• Based on type, the market is segmented into allergic rhinitis, asthma, food allergy, and others
• Based on geography, the allergy immunotherapies market is segmented into Europe, North America, Asia, and the Rest of World (ROW)
• For insights on the market contribution of each segment, buy the report!

Allergy immunotherapies market: Country-level analysis

The countries covered in the allergy immunotherapies market report are the UK, Germany, France, and Rest of Europe (Europe); the US and Canada (North America); China and India (Asia); and Brazil, Argentina, and Rest of the Middle East & Africa (ROW).

• Europe is estimated to account for 53% of the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The increasing prevalence of allergies in Germany, France, Italy, and the UK is driving market growth in the region.
• Food allergies are prevalent among a significant share of the adult population in Europe. Among the affected patients, the prevalence of oral allergy symptoms is the highest, followed by skin symptoms and rhino-conjunctivitis. The increasing need to treat these allergies is propelling the development of allergy immunotherapies in Europe, which will drive the regional market's growth during the forecast period.

The geographic landscape of the report also provides market-impacting factors and changes that impact current and future trends. For detailed information, request a sample!

Global allergy immunotherapies market: Dynamics & insights

Technavio's research report on allergy immunotherapies market provides analysis and insights about the various drivers, along with key challenges, that impact the market throughout the forecast period.

The increasing prevalence of allergies is notably driving the market growth. Some of the main reasons for this prevalence include the growing pollution and the increasing consumption of tobacco products such as cigarettes. In addition, various companies are conducting research on novel therapies, which have led to advances in the field of immunology therapeutics for allergies. These factors will fuel the growth of the market during the forecast period.

The failure of clinical trials for various allergens is impeding the market. Many allergies have unknown pathogenesis, which has resulted in the failure of clinical trials. For instance, In November 2019, ASIT biotech gp-ASIT+ failed to meet its Phase III trial primary endpoint. Similarly, in March 2019, Allergy Therapeutic's birch pollen product failed to meet its primary endpoint in the Phase III B301 trial. All these clinical trial failures will negatively affect the market position of firms, which, in turn, is expected to limit the growth of the market during the forecast period.

Allergy immunotherapies market: Competitive landscape and vendor analysis

Technavio's report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Some of the major players operating in the allergy immunotherapies market are Adamis Pharmaceuticals Corp., Aimmune Therapeutics Inc., ALK Abello AS, ALLERGOPHARMA GmbH and Co. KG, Allergy Therapeutics PLC, Biomay AG, DBV Technologies SA, Desentum Oy, HAL Allergy BV, Immunomic Therapeutics Inc., Jubilant Pharmova Ltd., LETI Pharma SLU, LOFARMA Spa, Merck KGaA, Novartis AG, Optum Inc., Shionogi and Co. Ltd., Stallergenes Greer Ltd., Torii Pharmaceutical Co. Ltd., and Viatris Inc., among others. For insights on the vendor offerings, download a PDF sample!

Related reports:

The autoimmune hemolytic anemia therapeutics market size is expected to grow by USD 268.22 million from 2021 to 2026 at an accelerating CAGR of 9.1%. This report extensively covers segmentation by product (corticosteroids, monoclonal antibodies, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

The immunoassay market size is expected to increase by USD 12.55 billion from 2021 to 2026, and the market's growth momentum will decelerate at a CAGR of 7.40%. This report extensively covers segmentation by product (reagents and kits and analyzers) and geography (North America, Europe, Asia, and ROW).

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

Browse for Technavio's healthcare market reports

Table of content:

1 Executive Summary

1.1 Market overview 

Exhibit 01: Executive Summary – Chart on Market Overview 

Exhibit 02: Executive Summary – Data Table on Market Overview 

Exhibit 03: Executive Summary – Chart on Global Market Characteristics 

Exhibit 04: Executive Summary – Chart on Market by Geography 

Exhibit 05: Executive Summary – Chart on Market Segmentation by Product 

Exhibit 06: Executive Summary – Chart on Market Segmentation by Type 

Exhibit 07: Executive Summary – Chart on Incremental Growth 

Exhibit 08: Executive Summary – Data Table on Incremental Growth 

Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 

2 Market Landscape 

2.1 Market ecosystem 

Exhibit 10: Parent market 

Exhibit 11: Market Characteristics 

3 Market Sizing 

3.1 Market definition 

Exhibit 12: Offerings of vendors included in the market definition 

3.2 Market segment analysis 

Exhibit 13: Market segments 

3.3 Market size 2022 

3.4 Market outlook: Forecast for 2022-2027

Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) 

Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)

Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)

Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 

4 Historic Market Size 

4.1 Global allergy immunotherapies market 2017 - 2021 

Exhibit 18: Historic Market Size – Data Table on Global allergy immunotherapies market 2017 - 2021 ($ million) 

4.2 Product Segment Analysis 2017 - 2021 

Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)

4.3 Type Segment Analysis 2017 - 2021 

Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million) 

4.4 Geography Segment Analysis 2017 - 2021 

Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 

4.5 Country Segment Analysis 2017 - 2021 

Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary 

Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 

5.2 Bargaining power of buyers 

Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 

5.3 Bargaining power of suppliers 

Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 

5.4 Threat of new entrants 

Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 

5.5 Threat of substitutes 

Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 

5.6 Threat of rivalry 

Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 

5.7 Market condition 

Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 

6 Market Segmentation by Product

6.1 Market segments 

Exhibit 30: Chart on Product - Market share 2022-2027 (%)

Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 

6.2 Comparison by Product 

Exhibit 32: Chart on Comparison by Product

Exhibit 33: Data Table on Comparison by Product 

6.3 SCIT - Market size and forecast 2022-2027 

Exhibit 34: Chart on SCIT - Market size and forecast 2022-2027 ($ million)

Exhibit 35: Data Table on SCIT - Market size and forecast 2022-2027 ($ million) 

Exhibit 36: Chart on SCIT - Year-over-year growth 2022-2027 (%) 

Exhibit 37: Data Table on SCIT - Year-over-year growth 2022-2027 (%) 

6.4 SLIT - Market size and forecast 2022-2027 

Exhibit 38: Chart on SLIT - Market size and forecast 2022-2027 ($ million) 

Exhibit 39: Data Table on SLIT - Market size and forecast 2022-2027 ($ million) 

Exhibit 40: Chart on SLIT - Year-over-year growth 2022-2027 (%) 

Exhibit 41: Data Table on SLIT - Year-over-year growth 2022-2027 (%) 

6.5 Market opportunity by Product 

Exhibit 42: Market opportunity by Product ($ million) 

7 Market Segmentation by Type 

7.1 Market segments 

Exhibit 43: Chart on Type - Market share 2022-2027 (%) 

Exhibit 44: Data Table on Type - Market share 2022-2027 (%) 

7.2 Comparison by Type 

Exhibit 45: Chart on Comparison by Type 

Exhibit 46: Data Table on Comparison by Type 

7.3 Allergic Rhinitis - Market size and forecast 2022-2027 

Exhibit 47: Chart on Allergic Rhinitis - Market size and forecast 2022-2027 ($ million) 

Exhibit 48: Data Table on Allergic Rhinitis - Market size and forecast 2022-2027 ($ million) 

Exhibit 49: Chart on Allergic Rhinitis - Year-over-year growth 2022-2027 (%) 

Exhibit 50: Data Table on Allergic Rhinitis - Year-over-year growth 2022-2027 (%)

7.4 Asthma - Market size and forecast 2022-2027 

Exhibit 51: Chart on Asthma - Market size and forecast 2022-2027 ($ million) 

Exhibit 52: Data Table on Asthma - Market size and forecast 2022-2027 ($ million) 

Exhibit 53: Chart on Asthma - Year-over-year growth 2022-2027 (%) 

Exhibit 54: Data Table on Asthma - Year-over-year growth 2022-2027 (%) 

7.5 Food Allergy - Market size and forecast 2022-2027 

Exhibit 55: Chart on Food Allergy - Market size and forecast 2022-2027 ($ million)

Exhibit 56: Data Table on Food Allergy - Market size and forecast 2022-2027 ($ million) 

Exhibit 57: Chart on Food Allergy - Year-over-year growth 2022-2027 (%) 

Exhibit 58: Data Table on Food Allergy - Year-over-year growth 2022-2027 (%) 

7.6 Others - Market size and forecast 2022-2027 

Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million) 

Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million)

Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%) 

Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%) 

7.7 Market opportunity by Type 

Exhibit 63: Market opportunity by Type ($ million) 

8 Customer Landscape 

8.1 Customer landscape overview 

Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape 

9.1 Geographic segmentation

Exhibit 65: Chart on Market share by geography 2022-2027 (%) 

Exhibit 66: Data Table on Market share by geography 2022-2027 (%) 

9.2 Geographic comparison 

Exhibit 67: Chart on Geographic comparison

Exhibit 68: Data Table on Geographic comparison 

9.3 Europe - Market size and forecast 2022-2027 

Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million) 

Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)

Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%) 

Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%) 

9.4 North America - Market size and forecast 2022-2027 

Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million) 

Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million) 

Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%) 

Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%) 

9.5 Asia - Market size and forecast 2022-2027 

Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million) 

Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) 

Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%) 

Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%) 

9.6 Rest of World (ROW) - Market size and forecast 2022-2027 

Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) 

Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) 

Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 

9.7 Germany - Market size and forecast 2022-2027 

Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million) 

Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million) 

Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%) 

Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%) 

9.8 France - Market size and forecast 2022-2027 

Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ million) 

Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ million)

Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%) 

Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%) 

9.9 US - Market size and forecast 2022-2027

Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ million) 

Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ million) 

Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%) 

Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%) 

9.10 UK - Market size and forecast 2022-2027 

Exhibit 97: Chart on UK - Market size and forecast 2022-2027 ($ million) 

Exhibit 98: Data Table on UK - Market size and forecast 2022-2027 ($ million) 

Exhibit 99: Chart on UK - Year-over-year growth 2022-2027 (%) 

Exhibit 100: Data Table on UK - Year-over-year growth 2022-2027 (%) 

9.11 Japan - Market size and forecast 2022-2027 

Exhibit 101: Chart on Japan - Market size and forecast 2022-2027 ($ million) 

Exhibit 102: Data Table on Japan - Market size and forecast 2022-2027 ($ million)

Exhibit 103: Chart on Japan - Year-over-year growth 2022-2027 (%) 

Exhibit 104: Data Table on Japan - Year-over-year growth 2022-2027 (%) 

9.12 Market opportunity by geography 

Exhibit 105: Market opportunity by geography ($ million) 

10 Drivers, Challenges, and Trends 

10.1 Market drivers 

10.2 Market challenges 

10.3 Impact of drivers and challenges 

Exhibit 106: Impact of drivers and challenges in 2022 and 2027 

10.4 Market trends 

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape 

Exhibit 107: Overview on Criticality of inputs and Factors of differentiation 

11.3 Landscape disruption 

Exhibit 108: Overview on factors of disruption 

11.4 Industry risks 

Exhibit 109: Impact of key risks on business 

12 Vendor Analysis 

12.1 Vendors covered

Exhibit 110: Vendors covered

12.2 Market positioning of vendors 

Exhibit 111: Matrix on vendor position and classification 

12.3 Adamis Pharmaceuticals Corp. 

Exhibit 112: Adamis Pharmaceuticals Corp. - Overview 

Exhibit 113: Adamis Pharmaceuticals Corp. - Business segments 

Exhibit 114: Adamis Pharmaceuticals Corp. - Key offerings 

Exhibit 115: Adamis Pharmaceuticals Corp. - Segment focus 

12.4 Aimmune Therapeutics Inc. 

Exhibit 116: Aimmune Therapeutics Inc. - Overview

Exhibit 117: Aimmune Therapeutics Inc. - Product / Service

Exhibit 118: Aimmune Therapeutics Inc. - Key offerings 

12.5 ALK Abello AS 

Exhibit 119: ALK Abello AS - Overview 

Exhibit 120: ALK Abello AS - Product / Service 

Exhibit 121: ALK Abello AS - Key offerings 

12.6 Allergy Therapeutics PLC

Exhibit 122: Allergy Therapeutics PLC - Overview 

Exhibit 123: Allergy Therapeutics PLC - Product / Service 

Exhibit 124: Allergy Therapeutics PLC - Key offerings 

12.7 DBV Technologies SA 

Exhibit 125: DBV Technologies SA - Overview 

Exhibit 126: DBV Technologies SA - Product / Service 

Exhibit 127: DBV Technologies SA - Key news 

Exhibit 128: DBV Technologies SA - Key offerings 

12.8 Desentum Oy 

Exhibit 129: Desentum Oy - Overview 

Exhibit 130: Desentum Oy - Product / Service 

Exhibit 131: Desentum Oy - Key offerings 

12.9 HAL Allergy BV 

Exhibit 132: HAL Allergy BV - Overview 

Exhibit 133: HAL Allergy BV - Product / Service 

Exhibit 134: HAL Allergy BV - Key offerings 

12.10 Immunomic Therapeutics Inc. 

Exhibit 135: Immunomic Therapeutics Inc. - Overview 

Exhibit 136: Immunomic Therapeutics Inc. - Product / Service 

Exhibit 137: Immunomic Therapeutics Inc. - Key offerings 

12.11 Jubilant Pharmova Ltd.

Exhibit 138: Jubilant Pharmova Ltd. - Overview 

Exhibit 139: Jubilant Pharmova Ltd. - Business segments 

Exhibit 140: Jubilant Pharmova Ltd. - Key news 

Exhibit 141: Jubilant Pharmova Ltd. - Key offerings 

Exhibit 142: Jubilant Pharmova Ltd. - Segment focus 

12.12 LETI Pharma SLU 

Exhibit 143: LETI Pharma SLU - Overview 

Exhibit 144: LETI Pharma SLU - Product / Service 

Exhibit 145: LETI Pharma SLU - Key offerings

12.13 LOFARMA Spa 

Exhibit 146: LOFARMA Spa - Overview 

Exhibit 147: LOFARMA Spa - Product / Service 

Exhibit 148: LOFARMA Spa - Key offerings 

12.14 Merck KGaA 

Exhibit 149: Merck KGaA - Overview 

Exhibit 150: Merck KGaA - Business segments 

Exhibit 151: Merck KGaA - Key news 

Exhibit 152: Merck KGaA - Key offerings 

Exhibit 153: Merck KGaA - Segment focus 

12.15 Novartis AG 

Exhibit 154: Novartis AG - Overview 

Exhibit 155: Novartis AG - Business segments 

Exhibit 156: Novartis AG - Key offerings 

Exhibit 157: Novartis AG - Segment focus 

12.16 Stallergenes Greer Ltd.

Exhibit 158: Stallergenes Greer Ltd. - Overview 

Exhibit 159: Stallergenes Greer Ltd. - Product / Service 

Exhibit 160: Stallergenes Greer Ltd. - Key offerings 

12.17 Viatris Inc. 

Exhibit 161: Viatris Inc. - Overview 

Exhibit 162: Viatris Inc. - Business segments 

Exhibit 163: Viatris Inc. - Key offerings 

Exhibit 164: Viatris Inc. - Segment focus 

13 Appendix 

13.1 Scope of the report 

13.2 Inclusions and exclusions checklist 

Exhibit 165: Inclusions checklist 

Exhibit 166: Exclusions checklist 

13.3 Currency conversion rates for US$ 

Exhibit 167: Currency conversion rates for US$ 

13.4 Research methodology 

Exhibit 168: Research methodology 

Exhibit 169: Validation techniques employed for market sizing 

Exhibit 170: Information sources 

13.5 List of abbreviations 

Exhibit 171: List of abbreviations 

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio